Drug intelligence / Profile preview

TLQP-21 + N-acetylcysteine

Development stage
Unknown
Modality
Peptides, Small Molecules
Administration
Intracerebroventricular, Intravenous
01

Overview

This is a combination of two active substances: TLQP-21, a 21-amino acid peptide derived from the VGF protein (spanning residues 556-576), and N-acetylcysteine (NAC), an antioxidant compound. TLQP-21 is a multifunctional neuropeptide that acts as a Complement 3a receptor (C3aR1) agonist[4][5]. The peptide increases energy expenditure, promotes lipolysis in adipose tissue, prevents diet-induced obesity, and has neuroprotective properties[1][2][3]. It activates G-protein coupled receptor signaling pathways, leading to phospholipase C beta (PLCβ) activation, intracellular calcium mobilization, and downstream effects including ERK1/2 and AKT phosphorylation[5]. TLQP-21 increases sympathetic nervous system activity, upregulates β3-adrenergic receptors and PPAR-δ in white adipose tissue, and enhances energy expenditure through fatty acid oxidation and energy uncoupling[1][3]. N-acetylcysteine is an antioxidant that has been developed as a capping agent for gold nanocages containing TLQP-21 for potential neuroprotective applications[6][7]. The combination has been investigated in nanoformulations for metabolic and neurological applications.

Other names
TLQP21 + NAC
02

Targets

C3AR1 (Complement C3a receptor)HSPA8 (Heat shock cognate 71 kDa protein)

Beyond the preview

Go deeper on TLQP-21 + N-acetylcysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLQP-21 + N-acetylcysteine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call